Skip to search formSkip to main contentSkip to account menu

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

In the recent outbreak of novel coronavirus infection in Wuhan, China, significantly abnormal coagulation parameters in severe novel coronavirus pneumonia (NCP) cases were a concern.
View on Elsevier (opens in a new tab)

Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy

A relatively high mortality of severe coronavirus disease 2019 (COVID‐19) is worrying, and the application of heparin in COVID‐19 has been recommended by some expert consensus because of the risk of…
View on Elsevier (opens in a new tab)

ISTH interim guidance on recognition and management of coagulopathy in COVID‐19

This work aims to contribute towards the humanizing of thrombosis and Haemostasis by promoting awareness of the importance of proper diagnosis and treatment of these conditions in patients.
View on Wiley (opens in a new tab)

Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2

Patients with severe pneumonia induced by SARS-CoV2 had higher platelet count than those induced by non-SARS- CoV2, and only the former with markedly elevated D-dimer may benefit from anticoagulant treatment.
View on Springer (opens in a new tab)

Profile of natural anticoagulant, coagulant factor and anti-phospholipid antibody in critically ill COVID-19 patients

Sustained hypercoagulable status and thrombotic events were common in critically ill patients with COVID-19, and the low activities of natural anticoagulants, elevated factor VIII level and the presence of antiphospholipid antibodies, together, may contribute to the etiopathology of coagulopathy in CO VID-19 patients.
View on Springer (opens in a new tab)

Coagulation dysfunction: A hallmark in COVID-19.

The mechanisms of COVID-19 underlying coagulation activation are discussed and the implications for anticoagulant and thrombolytic treatment in the management of CO VID-19 are discussed, which provide opportunities to prevent or reduce "excessive" thrombin generation, while preserving "adaptive" hemostasis.
View on PubMed (opens in a new tab)

Type and dose of heparin in Covid‐19: Reply

Although unfractionated heparin (UFH) has been used for several years, it does have practical issues, mainly with respect to the need for frequent monitoring using the activated partial thromboplastin times (aPTT).
View on Elsevier (opens in a new tab)

Time course of soluble P-selectin and von Willebrand factor levels in trauma patients: a prospective observational study

Lower levels of sPsel and VWF on admission were associated with the presence of coagulopathy and might not predict a better outcome and an increase in the VWF level at the end of the first week after admission to ICU was associated with increased 30-day mortality.
View on Springer (opens in a new tab)

Validation of the PLASMIC score, a clinical prediction tool for thrombotic thrombocytopenic purpura diagnosis, in Chinese patients.

View on PubMed (opens in a new tab)

Laboratory haemostasis monitoring in COVID‐19

The authors used D-dimer cut-off of 1.5 µg/mL for predicting venous TE and demonstrated sensitivity and specificity and specificity, and suggested D-dimers may be used to monitor the effectiveness of anticoagulants although this practice is not universally accepted.
View on Elsevier (opens in a new tab)
...
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)